

BLAU FARMACÊUTICA S.A.

Publicly Held Company
NIRE 35.300.416.406
CVM Code No. 2462-7

NOTICE TO SHAREHOLDERS**Auction of Capital Increase Shares with Bonus Shares**

BLAU FARMACÊUTICA S.A. (Ticker: **BLAU3**; "**Blau**" or "**Company**"), hereby informs its shareholders and the market in general, in addition to the notice to shareholders disclosed on December 29, 2025, of the following.

On February 6, 2026, the trading period for fractional shares ended, and the remaining fractions were separated and grouped into 4,586 common shares issued by the Company ("Consolidated Shares").

The Consolidated Shares will be sold at an auction to be held on **March 10, 2026**, at B3 S.A. – Brasil, Bolsa, Balcão ("B3"), with the reference price being the closing price of the shares on the trading day immediately preceding the date of the auction ("Auction").

If the Consolidated Shares are not fully sold at the Auction, Itaú Corretora de Valores S.A., the institution responsible for bookkeeping the Company's shares ("Itaú Corretora"), will record the remaining amount in the closing auctions of subsequent trading sessions until all shares are sold or up to a limit of five (5) consecutive trading sessions.

The net proceeds obtained from the sale of the Consolidated Shares at the Auction will be apportioned and distributed proportionally among the holders of fractional shares, according to their respective shareholdings at the end of the fractional trading period. The payment date will be communicated by the Company in due course, in accordance with the deadlines and operating procedures of B3 and Itaú Corretora.

The distribution of the amounts will occur as follows:

- a) shareholders with complete registration data: the amounts will be deposited in the checking account indicated in the respective shareholder's registration;
- b) shareholders with shares deposited at the B3 Central Depository: the amounts will be credited directly to the Central Depository, which will be responsible for passing them on to the respective shareholder through its custodian; and
- c) other unidentified shareholders or shareholders without complete registration data: the amounts will be available at the Company, for the legal period, for receipt by the respective holder upon provision of complete registration data.

The funds allocated to investors, whether resident or non-resident in Brazil may be subject to income tax on any capital gains, which will be taxed as "net gains" under current legislation. Therefore, the appropriate tax treatment should be identified directly by the respective shareholders, with the assistance of their advisors.

The Company will keep its shareholders and the market informed regarding the outcome and conclusion of the auction.

Cotia, March 6, 2026

Douglas Leandro Rodrigues
Chief Financial and Investor Relations Officer

About Blau Farmacêutica:

Blau is a leading multinational pharmaceutical company in the hospital segment and a pioneer in biotechnology in Brazil, with a portfolio of proprietary brands of highly complex medicines focused on relevant segments in the industry, such as immunology, hematology, oncology, nephrology, infectious diseases, and several other therapeutic classes. Blau has an international presence, operating in Brazil and seven other Latin American countries (Argentina, Colombia, Chile, Ecuador, Mexico, Peru, and Uruguay), in addition to a plasma collection operation in the United States. It has a modern pharmaceutical industrial complex in Brazil, consisting of five industrial plants with state-of-the-art technology, dedicated to serving the local market and exports.